Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NICE approves another anti-TNF

Certolizumab pegol (Cimzia) has been added to the tumour necrosis factor (TNF) inhibitors that can used to treat rheumatoid arthritis in the latest round of National Institute for Health and Clinical Excellence guidance, published this week.

By Newsteam

Certolizumab pegol (Cimzia) has been added to the tumour necrosis factor (TNF) inhibitors that can used to treat rheumatoid arthritis in the latest round of National Institute for Health and Clinical Excellence guidance, published this week.

The guidance advises that certolizumab pegol can be prescribed for the treatment of active rheumatoid arthritis in adults in England and Wales whose response to two disease-modifying antirheumatic drugs, including methotrexate, has been inadequate. TNF inhibitors adalimumab, etanercept and infliximab were approved for this indication by NICE in 2007 (PJ, 27 October 2007, p461) and the same conditions of use apply to certolizumab pegol.

Manufacturer UCB Pharma will provide the first 12 weeks of certolizumab pegol free through a patient access scheme agreed with the Department of Health, says NICE.

Trabectedin approved

NICE also released guidance today on trabectedin (Yondelis) for the treatment of certain patients with advanced soft tissue sarcoma. The drug can be prescribed if treatment with  anthracyclines and ifosfamide has failed or if patients are intolerant of or have contraindications to these treatments. Manufacturer PharmaMar has agreed to meet the costs of the drug for any therapy needed beyond the fifth cycle of treatment, says NICE.

Citation: The Pharmaceutical Journal URI: 10998737

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.